These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 30379691)
1. Successful use of the potent enzyme inducer enzalutamide in a treatment-experienced HIV-positive male with prostate cancer. Nhean S; Bravo J; Sheehan NL; Walmsley S; Tilley D; Tseng AL AIDS; 2018 Nov; 32(17):2640-2642. PubMed ID: 30379691 [No Abstract] [Full Text] [Related]
2. Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer. Antonarakis ES Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691 [No Abstract] [Full Text] [Related]
3. Enzalutamide (Xtandi) for prostate cancer. Med Lett Drugs Ther; 2013 Mar; 55(1411):e20. PubMed ID: 23467121 [No Abstract] [Full Text] [Related]
4. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide. Attard G; Antonarakis ES Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988 [No Abstract] [Full Text] [Related]
5. Lack of interaction between enzalutamide and warfarin in a metastatic castration-resistant prostate cancer patient. Casserly EA; Rogers SE; Keisner SV J Oncol Pharm Pract; 2017 Jan; 23(1):68-70. PubMed ID: 26454199 [TBL] [Abstract][Full Text] [Related]
6. The evolving role of enzalutamide on the treatment of prostate cancer. Nadal R; Bellmunt J Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021 [TBL] [Abstract][Full Text] [Related]
7. Falsely Elevated Digoxin Levels in Patients on Enzalutamide. Kalra D; Tesfazghi M Circ Heart Fail; 2020 Jul; 13(7):e007008. PubMed ID: 32527146 [No Abstract] [Full Text] [Related]
8. The role of enzalutamide in the treatment of castration-resistant prostate cancer. Rawlinson A; Mohammed A; Miller M; Kunkler R Future Oncol; 2012 Sep; 8(9):1073-81. PubMed ID: 23030482 [TBL] [Abstract][Full Text] [Related]
17. Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer. Westdorp H; Kuip EJM; van Oort IM; Kramers C; Gerritsen WR; Vissers KCP J Pain Symptom Manage; 2018 Apr; 55(4):e6-e8. PubMed ID: 29175468 [No Abstract] [Full Text] [Related]
18. New prostate cancer drugs hold promise. Cancer; 2013 Jan; 119(2):247-8. PubMed ID: 23292897 [No Abstract] [Full Text] [Related]
19. Age Adjusted Charlson Comorbidity Index Strongly Influences Survival, Irrespective of Performance Status and Age, in Patients With Advanced Prostatic Cancer Treated With Enzalutamide. VAN Halteren HK; Vreugdenhil G Anticancer Res; 2019 Feb; 39(2):863-866. PubMed ID: 30711968 [TBL] [Abstract][Full Text] [Related]
20. The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study. Cicero G; DE Luca R; Dorangricchia P; Dieli F Anticancer Res; 2017 Mar; 37(3):1475-1480. PubMed ID: 28314320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]